EPR: Evidence and fallacy.

By Joseph W. Nichols, You Han Bae. Journal of Controlled Release, 2014

731 citations recorded by the source corpus.

Subfields: Biomaterials, Biophysics, Materials Chemistry

View Paper: https://www.semanticscholar.org/paper/a72343b8ab0d9b983dd5213b7c6414eddf2111c6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. Jun Wu
2. S. Mitragotri
3. F. Danhier
4. A. Anselmo
5. Daniel G. Anderson
6. V. Préat
7. Robert Langer
8. S. Hua

In Biophysics

1. Jun Wu
2. G. Storm
3. F. Danhier

In Materials Chemistry

1. A. Anselmo
2. S. Mitragotri
3. Jun Wu
4. G. Storm
5. F. Danhier

Citations in the corpus

• The Enhanced Permeability and Retention (EPR) Effect: The Significance of the Concept and Methods to Enhance Its Application (2021, methodology): “Some doubt the usefulness of the EPR effect in clinical practice by using the example of Doxil, a polyethylene glycol (PEG) modified-liposome formulation of doxorubicin, which does not appear to significantly improve the benefits of solid tumor treatment compared with parental free drug doxorubicin ”
• Nanoparticles in the clinic (2016, background): “An example of this is the EPR effect, which has certainly been established in small animal models, however, similar evidence is lacking for humans.(121) Other issues arising from issues relating human and animal experiments include optimization of targeting ligands, where optimization of the number ”
• Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures (2017, background): “The clinical therapeutic efficacy of Doxil was superior in ovarian cancers and AIDS-related Kaposi’s sarcoma compared to standard therapies, while equivalent in multiple myeloma and metastatic breast cancer [15,16].”
• Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization (2018, background): “For example, Doxil R © (pegylated liposomal doxorubicin) is the first FDA-approved NNM and has demonstrated superior efficacy in ovarian cancer and AIDS-related Kaposi’s sarcoma compared to standard conventional therapies (Nichols and Bae, 2014).”